Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Commenting on California’s Prop 71 to fund stem cell research, my blogging colleague David Appell makes an excellent point about stem cells and Alzheimer’s, but he may be overstating the case a bit. An increasingly frequent–and legitimate–criticism of proponents of embryonic stem cell research is their tendency to link the cells with a treatment for Alzheimer’s (and tie such research to a legacy for President Reagan). However, as researchers point out, even if stem cells do not pan out as a therapy for Alzheimer’s, studies using the cells will still help patients by increasing our understanding of the disease. Such research could even lead to a new drug or other treatment that doesn’t use ES cells.

Singling out the tenuous Alzheimer’s link as a tactic being used to “sell” California voters on stem cells strikes me as a bit disingenuous. As David notes, there are at least 70 diseases, many of them common, such as diabetes and heart disease, that might be treated with stem cells. And there are countless others, such as Alzheimer’s and almost any form of cancer, that could be better understood through research using embryonic stem cells (as well as adult stem cells). It is indeed better to be up front with voters–about both the limits and the incredible potential of research on all types of stem cells.

0 comments about this story. Start the discussion »

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me